Our products

In accordance with article L.51212-1-1-3 of the Public Health Code, hereinafter the list of drugs marketed by H.A.C Pharma and for which the laboratory is responsible for placing on the market.

The Summaries of Product Characteristics, notices and transparency notices for these specialties are available via the following link:

Public drug database

Cardiology

Aldomet®

Dci

Methyldopa

Therapeutic class

Antihypertensive

ATC code

C02AB02

Pharmaceutical form

Coated tablet 250 mg

Coated tablet 500 mg

HAS evaluation of the Aldomet®

Summary of product characteristics of the Aldomet®

Trandate®

Dci

Labetalol

Therapeutic class

Beta-blocker

ATC code

C07AG01

Pharmaceutical form

200 mg tablet

5mg/ml Solution for injection

HAS evaluation of the Trandate®

Summary of product characteristics of the Trandate®

Endocrinology

Flucortac®

Dci

Fludrocortisone

Therapeutic class

mineral corticoids

ATC code

H02AA02

Pharmaceutical form

50 µg scored tablet

HAS evaluation of the Flucortac®

Summary of product characteristics of the Flucortac®

Flucortac® oral solution

Dci

Fludrocortisone (acétate)

Therapeutic class

Mineralocorticoids

ATC code

H02AA02

Pharmaceutical form

100 micrograms/mL, oral solution

HAS evaluation of the Flucortac® oral solution

Summary of product characteristics of the Flucortac® oral solution

Propylex®

Dci

Propylthiouracile

Therapeutic class

Antithyroïd

ATC code

H03BA02

Pharmaceutical form

50 mg tablet

HAS evaluation of the Propylex®

Summary of product characteristics of the Propylex®

Gastroenterology

Imurel®

Dci

Azathioprine

Therapeutic class

Immunosuppressant

ATC code

L04AX01

Pharmaceutical form

25 mg film-coated tablet

50 mg film-coated tablet

50 mg powder for solution for injection

HAS evaluation of the Imurel®

Summary of product characteristics of the Imurel®

Nutrition

Dialypro®

Dci

Therapeutic class

oral dietary supplement

ATC code

Pharmaceutical form

powder

HAS evaluation of the Dialypro®

Summary of product characteristics of the Dialypro®

Onco-hematology

Alkeran®

Dci

Melphalan

Therapeutic class

Chemotherapy

ATC code

L01AA03

Pharmaceutical form

2 mg film coated tablets

50 mg powder for solution for injection

HAS evaluation of the Alkeran®

Summary of product characteristics of the Alkeran®

Lanvis®

Dci

Thioguanine

Therapeutic class

Chemotherapy

ATC code

L01BB03

Pharmaceutical form

40 mg tablet

HAS evaluation of the Lanvis®

Summary of product characteristics of the Lanvis®

Myleran®

Dci

Busulfan

Therapeutic class

Chemotherapy

ATC code

L01AB01

Pharmaceutical form

2 mg film-coated tablet

HAS evaluation of the Myleran®

Summary of product characteristics of the Myleran®

Purinethol®

Dci

Mercaptopurine

Therapeutic class

Chemotherapy

ATC code

L01BB02

Pharmaceutical form

50 mg tablet

HAS evaluation of the Purinethol®

Summary of product characteristics of the Purinethol®

Rheumatology

Chrono-Indocid®

Chrono-Indocid® is distributed in Portugal

Chrono-Indocid® is distributed in Switzerland

Dci

Indometacine

Therapeutic class

Anti-inflammatory & Anti-rheumatism

ATC code

M01AB01

Pharmaceutical form

75 mg caps

HAS evaluation of the Chrono-Indocid®

Summary of product characteristics of the Chrono-Indocid®

Imurel®

Dci

Azathioprine

Therapeutic class

Immunosuppressant

ATC code

L04AX01

Pharmaceutical form

25 mg film-coated tablet

50 mg film-coated tablet

50 mg powder for solution for injection

HAS evaluation of the Imurel®

Summary of product characteristics of the Imurel®

Indocid®

Dci

Indometacine

Therapeutic class

Anti-inflammatory & Anti-rheumatism

ATC code

M01AB01

Pharmaceutical form

25 mg caps

100 mg suppository

HAS evaluation of the Indocid®

Summary of product characteristics of the Indocid®

Zyloric®

Dci

Allopurinol

Therapeutic class

Hypo-uricemic

ATC code

M04AA01

Pharmaceutical form

100 mg tablet

200 mg tablet

300 mg tablet

HAS evaluation of the Zyloric®

Summary of product characteristics of the Zyloric®

Areas of application